Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

导出 LinkOut

翻译打印收藏纠错

作者： Laura L,Hammitt ; Dean,Quinn ; Ewa,Janczewska ; Francisco J,Pasquel ; Richard,Tytus ; K,Rajender Reddy ; Katia,Abarca ; Ilsiyar M,Khaertynova ; Ron,Dagan ; Jennifer,McCauley ; Kyeongmi,Cheon ; Alison,Pedley ; Tina,Sterling ; Gretchen,Tamms ; Luwy,Musey ; Ulrike K,Buchwald

关键词 15-valent PCV PCV13 PPSV23 V114 pneumococcal vaccine

DOI 10.1093/ofid/ofab605

PMID 35146039

发布时间 2024-08-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Open forum infectious diseases

2022年9卷3期

ofab605页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

Open forum infectious diseases

相似文献

Open forum infectious diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

Open forum infectious diseases

相似文献

Open forum infectious diseases

相关期刊

检索历史清除